Thomas Civik was named Chief Executive Officer of Pyxis Oncology, Inc. As of November 6, 2026, Pyxis Oncology, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 30, 2026 to September 8, 2026, naming 2 appointments and 1 departure (Form 8-K, September 8, 2026).
Who owns Pyxis Oncology, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Pyxis Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Pyxis Oncology, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-30 to 2026-09-08. They name 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Pyxis Oncology, Inc. files it.
Also on the record for Pyxis Oncology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Stake report, Schedule 13G/A, by Laurion Capital Management LP | 5.16% of the class | 5%+ stakes | Source |
| October 9, 2026 | Stake report, Schedule 13G/A, by GordonMD Global Investments LP | 16.4% of the class | 5%+ stakes | Source |
| October 5, 2026 | Stake report, Schedule 13G, by Coastlands Capital LP | 5.42% of the class | 5%+ stakes | Source |
| October 2, 2026 | Stake report, Schedule 13G/A, by GordonMD Global Investments LP | 17.5% of the class | 5%+ stakes | Source |
| July 10, 2026 | Stake report, Schedule 13G, by BVF PARTNERS L P/IL | 9.99% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13G/A, by GordonMD Global Investments LP | 12.1% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G/A, by Laurion Capital Management LP | 7.72% of the class | 5%+ stakes | Source |
| October 14, 2025 | Stake report, Schedule 13G/A, by Millennium Management LLC | 1.3% of the class | 5%+ stakes | Source |
| September 23, 2025 | Stake report, Schedule 13G, by GordonMD Global Investments LP | 6.2% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.5% of the class | 5%+ stakes | Source |
| July 1, 2025 | Stake report, Schedule 13G, by Millennium Management LLC | 5.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Pyxis Oncology, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Pyxis Oncology, Inc. and the records around it.
Pyxis Oncology, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- GordonMD Global Investments LP also filed stake reports on 1 other company: Kyverna Therapeutics, Inc. (Nov 2025)
- Laurion Capital Management LP also filed stake reports on 2 other companies: IMMUNIC, INC. (Aug 2026), Rallybio Corp (Aug 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
Watch Pyxis Oncology, Inc.
Get an email when Pyxis Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pyxis Oncology, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pyxis Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pyxis Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-08 | In | Chief Executive Officer | 8-K, 2026-09-08 | ||
| 2026-09-08 | In | Chairman of the Board | 2026-09-04 | 8-K, 2026-09-08 | |
| 2026-09-08 | Out | 2026-09-04 | 8-K, 2026-09-08 | ||
| 2026-04-30 | Reported | not named in the filing | 8-K/A, 2026-04-30 |
Who leads Pyxis Oncology, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Thomas Civik, appointed (filed 2026-09-08).
- Chairman of the Board: Thomas Civik, appointed, effective 2026-09-04 (filed 2026-09-08).
New leaders reset buying decisions — get the Full Report on Pyxis Oncology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Pyxis Oncology, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Pyxis Oncology, Inc.Every change, in the filing's words
Appointed: Thomas Civik, Chief Executive Officer
On September 4, 2026, the Board of Directors (the "Board") of Pyxis Oncology, Inc. (the "Company") appointed Thomas Civik, the Company's Interim Chief Executive Officer, to serve as the Company's permanent Chief Executive Officer, effective immediately (the "Appointment").
Appointed: Thomas Civik, Chairman of the Board, effective 2026-09-04
Board Leadership and Committee Changes In connection with the Appointment, the Board determined to combine the roles of Chairman of the Board and Chief Executive Officer and appointed Mr. Civik as Chairman of the Board, effective September 4, 2026.
Departing: Santhosh Palani, effective 2026-09-04
Board Member Resignation and Related Matters On September 3, 2026, Dr. Santhosh Palani, Ph.D., CFA, notified the Company of his resignation as a member of the Company's Board and all committees on which he served, effective as of September 4, 2026.
- Mr. Civik will continue to serve as a member of the Board as a Class II director.
- Mr. Civik, age 57, has served as the Company's Interim Chief Executive Officer since February 2, 2026 and as a member of the Board since September 2021.
- Mr. Civik previously served as Chairperson of the Board of ImCheck Therapeutics and Repare Therapeutics Inc. through their respective acquisitions by Ipsen and XOMA Royalty Corporation.
- From April 2020 to May 2021, Mr. Civik served as President, Chief Executive Officer and a member of the board of directors at Five Prime Therapeutics, Inc., a biotechnology company.
- From November 2017 until September 2019, Mr. Civik served as Chief Commercial Officer of Foundation Medicine, Inc., a genomic profiling and molecular information company.
- From December 2000 to November 2017, Mr. Civik served in positions of increasing responsibility at Genentech, Inc. ("Genentech"), a biotechnology company, most recently serving as Vice President and Franchise Head leading the commercialization efforts for the Avastin, Tarceva, Tecentriq, and Alecensa, products.
- From July 1992 to December 2000, Mr. Civik served at Sanofi S.A. in sales and marketing roles of increasing responsibility.
- Mr. Civik received an M.B.A. in business strategy and marketing from the Kellogg School of Management at Northwestern University and a B.A. in political science from Saint Norbert College.
Reported
Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.
- On April 29, 2026 (the "Effective Date"), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan's separation from the Company.
- Dr. Sullivan's resignation from the Board of Directors was not the result of any dispute or disagreement with the Company or the Company's Board of Directors on any matter relating to the operations, policies or practices of the Company.
- Under the Separation Agreement, Dr. Sullivan will continue to receive her existing salary for 18 months and is entitled to continued health coverage for up to 12 months after the Effective Date.
- Additionally, the Compensation Committee of the Board approved the accelerated vesting of all unvested restricted stock units and unvested stock options previously granted to her and an extension of the post-termination exercise period for all of her accelerated stock options to December 31, 2030.
- The Separation Agreement also provides for a one-year post-separation non-solicitation covenant applicable to Dr. Sullivan and a one-year post-separation non-disparagement covenant applicable to both parties.
Tools for this story
Each opens in a new tab, filled in for Pyxis Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.